Silk Road Medical, Inc. announced the completion of enrollment in its pivotal ROADSTER study. The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally invasive procedure. The device under study is the Company’s Enroute Transcarotid Neuroprotection System (NPS), which incorporates proven surgical principles to protect the brain from a stroke during carotid angioplasty and stenting, and features a mechanism to divert dangerous debris away from the brain by temporarily reversing blood flow. Data from the trial will be used to support 510(k) clearance of the Enroute Transcarotid NPS as well as PMA approval of the Enroute Transcarotid Stent System.
Dr. Sumaira Macdonald, a leading expert in the field of carotid artery disease and the Company’s Chief Medical Officer, said, “Until now, carotid stents were typically placed via the femoral artery approach, which is about three feet from the culprit carotid stenosis, and requires navigation of catheters and other instruments through often hostile territory, increasing the risk of stroke during or immediately after the procedure,” she said. “We know that carotid stents are effective in preventing strokes in the long term, but we need a safer way to deliver them. The Silk Road procedure moves the access point to within inches of the stenosis to avoid at-risk steps and provides a surgically-inspired method of protecting the brain throughout the simplified procedure.”
By contrast, the gold standard carotid endarterectomy procedure requires a large incision in the neck and a surgery that carries some risk of nerve damage, bleeding, scarring and infection. The Silk Road procedure is designed to reduce these surgical risks as well. “Historically, there has not been a safe and effective minimally invasive procedure that could hold up to the clinical outcomes established by carotid endarterectomy. This new procedure may be it,” said Richard Cambria, MD, Chief, Division of Vascular and Endovascular Surgery at Massachusetts General Hospital and The Robert R. Linton MD Professor of Vascular and Endovascular Surgery at the Harvard Medical School. “The results from our center will be announced at the VEITH Symposium.” Dr. Cambria serves as the National Co-Principle Investigator for the ROADSTER trial.
Both the ENROUTE Transcarotid NPS and Stent System have been granted CE Mark. The ENROUTE NPS is limited by United States law to investigational use. The ENROUTE Transcarotid Stent System is not currently available in the United States.
Learn more about the Silk Road procedure in Cath Lab Digest’s interview with Dr. Richard Cambria at http://bit.ly/1nC0JFq (or at http://www.cathlabdigest.com/articles/Avoiding-Aortic-Arch-Using-Flow-Reversal-Carotid-Artery-Stenting-Silk-Road-System-Reduce-St).